Safety and efficacy of re-treatment with [177Lu]Lu-DOTA-Octreotate radionuclide therapy in progressive gastro-entero-pancreatic neuroendocrine tumours – a single centre experience
R-PRRT is feasible, tolerable and efficacious in achieving disease control in patients with progressive GEP NET.
Authors
- Grace Kong (ORCID: https://orcid.org/0000-0002-0834-6888)
- A. Ravikumar
- Javad Saghebi
- Ramin Alipour (ORCID: https://orcid.org/0000-0002-1248-0967)
- Kerry Jewell (ORCID: https://orcid.org/0000-0003-1426-0113)
- Emma Boehm (ORCID: https://orcid.org/0000-0001-7631-9147)
- Michael Fahey (ORCID: https://orcid.org/0000-0002-9057-7860)
- Raghava Kashyap (ORCID: https://orcid.org/0000-0002-1007-974X)
- Tim Akhurst
- Anthony Cardin
- Rodney J. Hicks (ORCID: https://orcid.org/0000-0002-0758-0824)
- Michael S. Hofman (ORCID: https://orcid.org/0000-0001-8622-159X)
- Michael Michael (ORCID: https://orcid.org/0000-0001-5954-7105)
Institutions
- The University of Melbourne (AU)
- Peter MacCallum Cancer Centre (AU)
- The Alfred Hospital (AU)
- St Vincent's Hospital Melbourne (AU)
- Victorian Comprehensive Cancer Centre (AU)
- Monash University (AU)
Publication Details
- Journal
- European Journal of Nuclear Medicine and Molecular Imaging
- Published
- 2025-03-26
- DOI
- https://doi.org/10.1007/s00259-025-07235-w
- Citations
- 4
- Primary Topic
- Neuroendocrine Tumor Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 5.42
Funders
- Prostate Cancer Foundation
- University of Melbourne
- Medical Research Council
- National Health and Medical Research Council